首页> 美国卫生研究院文献>other >KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD
【2h】

KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD

机译:KDOQI US对2012年KDIGO CKD血压管理临床实践指南的评论

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In response to the 2012 KDIGO (Kidney Disease: Improving Global Outcomes) guideline for blood pressure management in patients with chronic kidney disease not on dialysis, the National Kidney Foundation organized a group of US experts in hypertension and transplant nephrology to review the recommendations and comment on their relevancy in the context of current US clinical practice and concerns. The overriding message was the dearth of clinical trial evidence to provide strong evidence-based recommendations. For patients with CKD with normal to mildly increased albuminuria, goal blood pressure has been relaxed to ≤140/90 mm Hg for both diabetic and nondiabetic patients. In contrast, KDIGO continues to recommend goal blood pressure ≤130/80 mm Hg for patients with chronic kidney disease with moderately or severely increased albuminuria and for all renal transplant recipients regardless of the presence of proteinuria, without supporting data. The expert panel thought the KDIGO recommendations were generally reasonable but lacking in sufficient evidence support and that additional studies are greatly needed.
机译:为了响应2012年KDIGO(肾脏疾病:改善全球结局)指南中未进行透析的慢性肾脏疾病患者的血压管理,美国国家肾脏基金会组织了一组美国高血压和移植肾病专家来审查建议和评论在当前美国临床实践和关注的背景下了解它们的相关性。最重要的信息是缺乏临床试验证据,无法提供强有力的基于证据的建议。对于患有正常至轻度蛋白尿增加的CKD患者,糖尿病患者和非糖尿病患者的目标血压均已放松至≤140/ 90 mm Hg。相比之下,KDIGO继续为患有中度或重度白蛋白尿增加的慢性肾脏病患者以及所有肾移植受者(无论是否存在蛋白尿)建议目标血压≤130/ 80 mm Hg。专家小组认为,KDIGO的建议总体上是合理的,但缺乏足够的证据支持,因此迫切需要进行更多的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号